Endothelium is endowed with several biologically active molecules to protect vascular integrity and maintain vascular hemostasis. Prostacyclin (PGI2) is one of the important vasoprotective molecules. It inhibits platelet activation and aggregation, suppresses smooth muscle cell activation and migration, and inhibits monocyte activation. It also diminishes vasoconstrictor responses. Reduced local PGI2 synthesis due to endothelial injury may lead to excessive blood and vascular cell activation thereby accelerating thrombosis and neointimal proliferation. Systemic administration of PGI2 to augment local PGI2 concentration has limited success because of undesirable adverse effects. The applicant proposes to test whether local production of PGI2 at a damaged vascular site can be restored by gene transfer of PGI2 synthetic enzymes and the augmented local PGI2 synthesis can protect against vascular thrombosis. Biosynthesis of PGI2 from arachidonic acid (AA) is catalyzed by prostaglandin H synthase (PGHS, also called cyclooxygenase) which converts AA into PGG2 and than PGG2 to PGH2. PGH2 is further converted to PGI2 by prostacyclin synthase (PGIS). In preliminary studies, this group has shown that endothelial cell PGHS-1 levels are augmented by retrovirus- and adenovirus-mediated transfer of human PGHS-1 cDNA which is accompanied by a large increase in PGI2 synthesis. Administration of adenovirus-CMV-PGHS-1 into angioplasty-damaged pig carotid arteries resulted in a 5-fold increase in PGI2 synthesis. To further the investigation of vascular gene transfer, 5 specific aims are proposed: 1) to evaluate the effect of adenovirus-mediated prostaglandin H synthase-1 (PGHS-1) transfer on preventing thrombosis in experimental animal models; 2) to assess the effect of transfer of endothelial prostacyclin synthase (PGIS) alone and in combination with PGHS-1 gene on the extent and duration of PGI2 production in cultures endothelial cells in vitro and on preventing thrombosis in vivo; 3) to determine the effect of PGHS-1 and/or PGIS gene transfer on intimal hyperplasia in experimental animal models; 4) to evaluate non-viral vectors for transferring PGHS-1 and/or PGIS cDNAs for augmenting PGI2 synthesis in vasoprotection; and 5) to use the most effective of the above gene therapies and determine its efficacy in preventing thrombosis and intimal proliferation in atherosclerotic porcine coronary arteries.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL054839-03
Application #
2735269
Study Section
Cardiovascular and Pulmonary Research A Study Section (CVA)
Project Start
1996-08-01
Project End
2001-04-30
Budget Start
1998-07-01
Budget End
2001-04-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
University of Texas Health Science Center Houston
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77225
Anderson, H V; McNatt, J; Clubb, F J et al. (2001) Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries. Circulation 104:2331-7
Shelat, H S; Liu, T J; Hickman-Bick, D L et al. (2001) Growth suppression of human coronary vascular smooth muscle cells by gene transfer of the transcription factor E2F-1. Circulation 103:407-14
Zoldhelyi, P; Chen, Z Q; Shelat, H S et al. (2001) Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries. Proc Natl Acad Sci U S A 98:4078-83
Jax, T W; Eichstaedt, H C; Shelat, H S et al. (2000) [New antithrombotic therapy approaches in coronary heart disease--prospects for gene therapy] Z Kardiol 89:1072-83
Zoldhelyi, P; McNatt, J; Shelat, H S et al. (2000) Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor. Circulation 101:289-95
Zoldhelyi, P; Beck, P J; Bjercke, R J et al. (2000) Inhibition of coronary thrombosis and local inflammation by a noncarbohydrate selectin inhibitor. Am J Physiol Heart Circ Physiol 279:H3065-75
Zoldhelyi, P; Eichstaedt, H; Jax, T et al. (1999) The emerging clinical potential of cardiovascular gene therapy. Semin Interv Cardiol 4:151-65
Fujise, K; Stacy, L; Beck, P et al. (1997) Differential effects of endothelin receptor activation on cyclic flow variations in rat mesenteric arteries. Circulation 96:3641-6
Pakala, R; Willerson, J T; Benedict, C R (1997) Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96:2280-6